Veracyte Inc (VCYT)

$30.88 -0.98 (-3.08%)
Market Cap 2.43B
Revenue (ttm) 445.76M
Net Income (ttm) 24.14M
EPS (ttm) N/A
PE Ratio 34.63
Forward PE 36.94
Profit Margin 5.42%
Debt to Equity Ratio 0.00
Volume 615,100
Avg Vol 1,538,948
Day's Range N/A - N/A
Shares Out 78.67M
Stochastic %K 44%
Beta 2.07
Analysts Strong Sell
Price Target $40.22

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 243 6300
Fax: 650 243 6388
Address:
6000 Shoreline Court, Suite 300, South San Francisco, United States
PhishTourFunds
PhishTourFunds Sep. 5 at 3:13 PM
$VCYT
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 7:53 AM
$VCYT Great piece that accurately captures VCYT's current position. So if you want to refresh your understanding of VCYT or learn about VCYT for the first time, this is essential reading. https://beyondspx.com/quote/VCYT/veracyte-genomic-diagnostics-powerhouse-forging-a-path-to-sustained-profitability-nasdaq-vcyt#analysis
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 23 at 1:59 PM
$VCYT
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 19 at 1:26 AM
$VCYT I dream about setups like that…
0 · Reply
ManosDeDiamante07
ManosDeDiamante07 Aug. 18 at 2:57 PM
$VCYT Killing the game 😎💰
0 · Reply
DonZulu
DonZulu Aug. 14 at 4:28 AM
$VCYT oh shit how did i miss this last week
1 · Reply
PhishTourFunds
PhishTourFunds Aug. 13 at 8:37 PM
$VCYT That was the only order that filled unfortunately…stock now sitting over $30 🔥
1 · Reply
SilverEagle
SilverEagle Aug. 13 at 7:52 PM
$VCYT bulls turn.
1 · Reply
PhishTourFunds
PhishTourFunds Aug. 13 at 6:22 PM
$VCYT $30 💪
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 12 at 1:22 PM
$VCYT 22% and climbing 💪
0 · Reply
Latest News on VCYT
Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 10:31 PM EDT - 4 days ago

Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Sep 9, 2025, 9:00 AM EDT - 5 days ago

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 29, 2025, 8:30 AM EDT - 16 days ago

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Aug 27, 2025, 11:25 AM EDT - 18 days ago

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Aug 26, 2025, 10:18 AM EDT - 19 days ago

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Aug 26, 2025, 8:30 AM EDT - 19 days ago

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:20 AM EDT - 5 weeks ago

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Veracyte Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Veracyte Announces Second Quarter 2025 Financial Results

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Jul 17, 2025, 5:30 PM EDT - 2 months ago

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Jul 8, 2025, 4:05 PM EDT - 2 months ago

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 28, 2025, 4:05 PM EDT - 3 months ago

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

Veracyte to Participate in Upcoming Investor Conferences

May 20, 2025, 5:00 PM EDT - 4 months ago

Veracyte to Participate in Upcoming Investor Conferences

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:49 AM EDT - 4 months ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

Veracyte Announces First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 4 months ago

Veracyte Announces First Quarter 2025 Financial Results

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 25, 2025, 7:00 AM EDT - 5 months ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 22, 2025, 9:00 AM EDT - 5 months ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Apr 21, 2025, 4:05 PM EDT - 5 months ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 25, 2025, 4:05 PM EDT - 6 months ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Mar 19, 2025, 5:00 PM EDT - 6 months ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:32 AM EST - 7 months ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Feb 25, 2025, 10:16 AM EST - 7 months ago

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 PM EST - 7 months ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:05 PM EST - 7 months ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 14, 2025, 8:30 AM EST - 7 months ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 11, 2025, 8:30 AM EST - 7 months ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 5, 2025, 8:30 AM EST - 7 months ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Feb 4, 2025, 4:30 PM EST - 7 months ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Dec 5, 2024, 4:05 PM EST - 10 months ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:49 PM EST - 11 months ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Veracyte Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 11 months ago

Veracyte Announces Third Quarter 2024 Financial Results

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Oct 16, 2024, 6:43 PM EDT - 11 months ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 15, 2024, 8:45 AM EDT - 1 year ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 5:30 PM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 26, 2024, 9:00 AM EDT - 1 year ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 7, 2024, 2:08 PM EDT - 1 year ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:17 PM EDT - 1 year ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Veracyte Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jul 17, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 22, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

Veracyte Announces First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2024 Financial Results

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

May 6, 2024, 4:05 PM EDT - 1 year ago

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 22, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Apr 22, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Apr 16, 2024, 8:30 AM EDT - 1 year ago

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Feb 27, 2024, 5:55 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 9:24 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Feb 22, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Feb 21, 2024, 5:00 PM EST - 1 year ago

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

PhishTourFunds
PhishTourFunds Sep. 5 at 3:13 PM
$VCYT
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 7:53 AM
$VCYT Great piece that accurately captures VCYT's current position. So if you want to refresh your understanding of VCYT or learn about VCYT for the first time, this is essential reading. https://beyondspx.com/quote/VCYT/veracyte-genomic-diagnostics-powerhouse-forging-a-path-to-sustained-profitability-nasdaq-vcyt#analysis
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 23 at 1:59 PM
$VCYT
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 19 at 1:26 AM
$VCYT I dream about setups like that…
0 · Reply
ManosDeDiamante07
ManosDeDiamante07 Aug. 18 at 2:57 PM
$VCYT Killing the game 😎💰
0 · Reply
DonZulu
DonZulu Aug. 14 at 4:28 AM
$VCYT oh shit how did i miss this last week
1 · Reply
PhishTourFunds
PhishTourFunds Aug. 13 at 8:37 PM
$VCYT That was the only order that filled unfortunately…stock now sitting over $30 🔥
1 · Reply
SilverEagle
SilverEagle Aug. 13 at 7:52 PM
$VCYT bulls turn.
1 · Reply
PhishTourFunds
PhishTourFunds Aug. 13 at 6:22 PM
$VCYT $30 💪
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 12 at 1:22 PM
$VCYT 22% and climbing 💪
0 · Reply
ZacksResearch
ZacksResearch Aug. 12 at 12:51 PM
$VCYT surges 15.5% post-earnings — what's driving the momentum? 🚀 Adjusted EPS jumped 46.7% from the year-ago period, smashing estimates by 41.9%, with revenues up 13.8% year over year — thanks to strong Decipher and Afirma test growth 📈. Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2701823/vcyt-stock-gains-on-q2-earnings-and-revenue-beat-margins-up?cid=sm-stocktwits-2-2701823-body-7292&ADID=SYND_STOCKTWITS_TWEET_2_2701823_BODY_7292
0 · Reply
ZacksResearch
ZacksResearch Aug. 12 at 11:51 AM
$VCYT pops 15% after crushing Q2 🚀 Earnings and revenue topped estimates, with Decipher and Afirma driving growth — margins are expanding too. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2701823/vcyt-stock-gains-on-q2-earnings-and-revenue-beat-margins-up?cid=sm-stocktwits-2-2701823-teaser-7291&ADID=SYND_STOCKTWITS_TWEET_2_2701823_TEASER_7291
0 · Reply
GSTX7
GSTX7 Aug. 11 at 8:27 PM
$VCYT Took profit here from the lows. LOTS of potential for longs here. Think they might push it back from the $28 resistance. Will add if it does. Will cry if I'm wrong ... lol
0 · Reply
ManosDeDiamante07
ManosDeDiamante07 Aug. 10 at 10:17 PM
$VCYT
0 · Reply
DanaBlack
DanaBlack Aug. 8 at 8:08 PM
$VCYT sorry guys. Started a position here too that’s why it took a massive dump. I’m the stock killer.
0 · Reply
StockArbitrage
StockArbitrage Aug. 8 at 3:32 PM
$IXHL $VCYT want something less volatile? My call out @25. Showing momentum.
0 · Reply
DanaBlack
DanaBlack Aug. 8 at 2:06 PM
$BULL moving profits to $VCYT
0 · Reply
pmb0928
pmb0928 Aug. 8 at 1:54 PM
$VCYT This is a solid investment, institutions all over it. $30-32 by end of next week.
0 · Reply
StockArbitrage
StockArbitrage Aug. 7 at 6:37 PM
$VCYT Found another customer. https://finance.yahoo.com/news/helix-veracyte-partner-expand-access-130000554.html
0 · Reply
pmb0928
pmb0928 Aug. 7 at 2:54 PM
$VCYT This is such a solid company with continued growth and increased revenue. Institutions are all over it. Cathie Wood is all over it.
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 7 at 11:23 AM
$VCYT 💪
0 · Reply
StockArbitrage
StockArbitrage Aug. 6 at 9:57 PM
$IXHL Followers, Check out $VCYT huge earnings just released. Blackrock days ago doubled their shares to about 12 Million. Keep Watch on upside potential. Established Cancer AI genomic classifier company. I took shares at $25.
0 · Reply